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Abstract 
Purpose: This study sought to test the acceptability and feasibility of a nurse-led psycho-
educational intervention (NLPI) delivered in primary care to prostate cancer survivors, and to 
provide preliminary estimates of the effectiveness of the intervention. 
Methods: Men who reported an ongoing problem with urinary, bowel, sexual or hormone-
related functioning/vitality on a self-completion questionnaire were invited to participate. 
Participants were randomly assigned to the NLPI plus usual care, or to usual care alone. 
Recruitment and retention rates were assessed. Prostate-related quality of life, self-efficacy, 
unmet needs, and psychological morbidity were measured at baseline and 9 months. Health-
care resource use data was also collected. An integrated qualitative study assessed 
experiences of the intervention.  
Results: 61% eligible men (83/136) participated in the trial, with an 87% (72/83) completion 
rate.  Interviews indicated that the intervention filled an important gap in care following 
treatment completion, helping men to self-manage, and improving their sense of well-being. 
However, only a small reduction in unmet needs and small improvement in self-efficacy was 
observed, and no difference in prostate-related quality of life or psychological morbidity. 
Patients receiving the NLPI recorded more primary care visits, while the usual care group 
recorded more secondary care visits.  Most men (70%; (21/30)) felt the optimal time for the 
intervention was around the time of diagnosis/before the end of treatment.  
Conclusions: Findings suggest a nurse-led psycho-educational intervention in primary care 
is feasible, acceptable and potentially useful to prostate cancer survivors.   
Keywords: prostate cancer; randomised controlled trial; pilot trial; primary care; nurse-led 
intervention; feasibility; self-efficacy 
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Introduction 
Prostate cancer is the most common non-dermatological cancer in men in the Western 
world, with around 40,000 and 220,000 cases diagnosed annually in the United Kingdom and 
United States of America respectively (Cancer Research UK, 2015, National Cancer Institute, 
2015). As it is largely a disease of older men, increased PSA screening and improved survival 
rates, coupled with an ageing population means the prevalence of prostate cancer survivors 
is increasing dramatically (Maddams et al., 2012).  
Following treatment men frequently experience urinary, bowel and sexual functioning 
problems) which can significantly impact on quality of life and result in psychological 
problems (Hamdy et al., 2016, Smith et al., 2009, Watson et al., 2016). Previous studies have 
highlighted unmet supportive care needs and shortcomings with existing follow-up services 
for men with prostate cancer (Prostate Cancer UK, 2012, O'Brien et al., 2010, King et al., 
2015, Cockle-Hearne et al., 2013). The increasing demand for follow-up care is placing 
hospital outpatient clinics under strain, and they are not always able to meet the range of 
needs found in prostate cancer survivors. Alternative models of follow-up are required, and 
UK and US guidance now recommends follow-up outside the hospital setting soon after 
treatment finishes (National Institute For Health and Clinical Excellence, 2014, Skolarus et al., 
2014). There is increasing interest in the role of primary care (Watson et al., 2011, Rubin et 
al., 2015), and a recent Australian trial found that shared hospital/primary care follow-up for 
men with low- to moderate risk prostate cancer is feasible and appears to produce clinically 
similar outcomes to those of standard care (Emery et al., 2017). Guided by the Medical 
Research Council (UK) Framework for the development and evaluation of complex 
interventions (Craig et al., 2008), in the PROSPECTIV study we have developed a nurse-led 
psycho-educational intervention (NLPI) based in primary care, aiming to improve prostate 
cancer-related quality of life, self-efficacy, psychological well-being and to reduce unmet 
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needs. We report here the findings from a pilot randomised controlled trial (RCT), which 
aimed to test the feasibility and acceptability of the intervention and to provide preliminary 
estimates of effectiveness and cost-effectiveness to inform the design of a future Phase III 
RCT  
Subjects and Methods 
In reporting the pilot trial methods and findings we referred to the TIDieR checklist which 
provides a template for intervention description and replication (Hoffmann et al., 2014). 
Feasibility of the study design was assessed with reference to ADePT framework (Bugge C et 
al, 2013). 
Design, setting and subjects 
The study was conducted in two phases, as summarised in Figure 1. Men were recruited to 
Phase 1 from cancer centres in two areas in England – Oxford University Hospitals Trust and 
Cambridge University Hospital NHS Trust. Men were eligible if their disease was stable as 
judged by the most recently available PSA result, and they had been treated with surgery, 
radiotherapy (including brachytherapy), androgen deprivation therapy (ADT) or active 
surveillance. Recruitment details for Phase 1 have been published elsewhere (Watson et al., 
2014, Watson et al., 2016). Participants completed a baseline questionnaire (RR-64%), and 
indicated on this questionnaire if they were interested in participating in a pilot trial of the 
NLPI.  
Men who expressed interest in the pilot trial and who indicated an ongoing problem (small, 
moderate or large) with urinary, bowel, sexual or hormone-related functioning/vitality on the 
EPIC-26 measure were contacted by telephone and, if willing, consented to participate in the 
pilot trial (Phase 2)(Watson et al., 2014). We aimed to recruit 80 men to the pilot trial 
(sufficient for assessing feasibility and acceptability outcomes and to provide an indication of 
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likely effect sizes and associated variation to inform power calculations for a future trial). 
Anticipating an uptake rate of approximately 60%, we therefore invited 136 of the 177 
eligible men to participate in the trial. Selection for invitation was sequential according to 
time of receipt of baseline questionnaire. Participants were then randomly assigned 1:1 to 
the intervention or control group. Randomisation was stratified by treatment into three 
groups: surgery; radiotherapy; ADT alone or active surveillance (combined because of small 
numbers). Participants were allocated to a randomisation group by the study co-ordinator on 
entry to the study using a random allocation spreadsheet provided by the statistician. 
Intervention (NLPI) 
The intervention was a nurse-delivered psycho-educational intervention, based on a self-
management approach (de Silva, 2011, Cockle-Hearne and Faithfull, 2010) underpinned by 
Bandura’s Social Cognitive Theory (1977) andencompassing the following four domains: 
understanding the context of prostate cancer treatment; eliciting needs; self-management 
and behavioural activation; cognitive restructuring (identification of specific situations or 
thought patterns that cause distress and tailored support for managing these, or onward 
referral if required). Further details are provided elsewhere (Watson et al., 2014).  
 
Appointment of the study nurses varied by Region, according to local funding arrangements. 
The study nurses included practice nurses(n=2)(Oxfordshire), who had no prior research 
experience and who expressed interest in participating in the study to one of the 
investigators (PR), or primary care research nurses (n=3) recruited through the East of 
England Primary Care Research Network who had no prior experience of caring for men with 
prostate cancer.  All  study nurses received two days of intensive training which included: 
information on the best available evidence for the management of treatment side effects; 
guidance on dealing with psychological issues; communication skills training; information on 
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study procedures; and guidance on when and how to refer men to their general practitioner 
(GP), secondary care or other support services e.g. incontinence and counselling services. 
They were also provided with written materials from Prostate Cancer UK and Macmillan 
Cancer Support to give to participants as appropriate. The training was delivered by a range 
of relevant experts and included sessions on managing urinary, bowel and sexual dysfunction 
and hormone-related problems, communication skills, role playing sessions, and an 
introduction to resources available via Prostate Cancer UK.  The training was accompanied by 
an intervention manual .  (Further details of the training are available from the authors on 
request). A second training session took place six weeks later where nurses were able to 
discuss experiences of pilot intervention delivery sessions. Regular monitoring and feedback 
was provided throughout the study (via monthly teleconferences with the lead study 
clinicans (PR/SF), the study PI and trial administrator (EW/EF) to ensure intervention fidelity.  
 
Intervention delivery involved an initial face-to face appointment in the patient’s own 
general practice.  These appointments were tailored to the specific problems of the patient, 
with nurses using the completed Phase 1 questionnaires as a prompt. Further nurse contact 
(either face-to-face or telephone) was individually tailored, according to need. All men 
received a final follow-up telephone call at 6 months.  Wherever possible, a single nurse took 
responsibility for each patient throughout the delivery of the intervention.  
Study nurses were not responsible for routine PSA monitoring. 
Outcome measures 
We measured prostate-related quality of life using the Expanded Prostate Cancer Index 
Composite-26 item version (EPIC-26) (Szymanski et al., 2010), unmet needs using the 
Supportive Care Needs Survey 34 item version (SCNS-SF34) (Boyes et al., 2009), and 
psychological wellbeing using the Hospital Anxiety and Depression Scale (HADS) (Zigmond 
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and Snaith, 1983). We used the Cancer Survivors Self-Efficacy Scale, a modified version of the 
Self Efficacy for Managing Chronic Disease Scale (Lorig, 2001) to measure respondents’ 
confidence in performing 11 behaviours (Foster et al., 2013). Participants completed these 
measures at baseline and at nine months. No primary outcome measure was specified, as 
this was a pilot trial. Participants were also asked to complete a health service resource use 
questionnaire  over three separate time periods; 0-3 months, >3-6 months, >6-7 months to 
record their prostate-related health service contacts, use of medication/devices, and sick 
days preventing usual activities. This information, plus self-reported health status as 
measured by the EQ-5D-5L and EQ-5D VAS (Brooks, 1996), was used to assess the cost-
effectiveness of the intervention where quality adjusted survival (QAS) was the primary 
outcome measure. The follow-up questionnaire also included questions seeking views on the 
intervention. Further details of the measures used (Watson et al., 2014) and the cost-
effectiveness analysis are reported elsewhere (Burns et al, 2017). 
Qualitative evaluation  
A maximum variation sample of men who received the intervention (by Region, treatment 
group, age and study nurse who delivered the intervention) were invited to participate in a 
semi-structured telephone interview (conducted by either EW or LM) to seek their 
experiences and views of the intervention. Interviews were conducted following the end of 
the intervention (mean time = 4 months, range 1-5 months post final nurse telephone follow-
up call). Interviews with each of the study nurses were also conducted at the end of the trial. 
Nurses were asked about their experiences of delivering the intervention and any challenges 
they encountered, their views regarding the training they had received, and their views on 
the potential usefulness of this model of follow-up.  
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All interviews were digitally recorded and transcribed verbatim, and any identifiable 
information was anonymised. In addition, all free text data were extracted from relevant 
sections of the study follow-up questionnaire.  
Data analyses 
Quantitative data were analysed in accordance with the manual for each measure included in 
the questionnaire. Scores were summarised using means and standard deviations, unless 
heavy skewness warranted the use of medians and interquartile ranges. Missing data is 
reported; no imputation was carried out. For the EPIC-26, we also assessed change in the 
proportion of those reporting moderate or large problems within each domain. Significance 
testing was not routinely carried out for all items as the study was not powered for such 
analysis and due to multiplicity issues.  Resource use differences across trial arms were 
assessed using Pearson's chi-squared test and associated p values were reported. Mean 
differences between baseline and seven month follow-up were instead calculated, with 95% 
confidence intervals. Where confidence intervals suggested statistically significant 
differences within groups, ANCOVA analyses were carried out to compare the averages 
across groups, adjusting for baseline results.  
The qualitative data from the patient and nurse interviews, together with the (generally 
short) free text data from the follow-up questionnaire, were analysed thematically. Data 
collection and analysis occurred simultaneously and iteratively, so initial themes which arose 
were explored further in subsequent interviews. Common themes were constructed, and 
similarities and differences between participants examined. Patient and nurse interviews 
were examined individually and then collectively to explore similarities and differences in 
their experiences of the intervention. Finally, overarching themes for the combined data 
were generated, and confirmed by consensus within the larger research group. 
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Results 
Feasibility and acceptability 
Feasibility of the study design was assessed with reference to the ADePT framework (A 
Process for Decision-making after Pilot and Feasibilty trials (Bugge C et al, 2013).  
Recruitment and randomisation 
Recruitment to the study was acceptable. Of those eligible and invited to participate in the 
trial following Phase 1 (n=136), 42 were randomised to the intervention group and 41 to the 
control group (n=83, 61% in total). No participants withdrew from the study subsequent to 
group allocation, indicating acceptability of the randomisation process. Demographic and 
treatment characteristics of the trial participants are presented in Table 1. No notable 
differences were observed between the two groups. Despite stratifying randomisation by 
treatment type, our participant group did consist of more surgical patients than any other 
treatment group. In a larger study, we would expect that stratified randomisation would be 
more effective. 
Retention 
Two patients in the intervention group discontinued the intervention: one man withdrew on 
account of disease progression, and one for other health reasons. All men in the intervention 
group attended the first nurse appointment. The follow-up questionnaire was completed by 
38 (95%) and 34 (83%) men in the intervention and control groups, respectively. Completion 
rate of individual measures was high, in particular, the SCNS-SF34 and the Cancer Survivors 
Self-Efficacy Scale which was fully completed by all respondents.  Thirty men provided free 
text comments relating to their experiences and views of the intervention.  
Delivery of intervention 
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In all cases it was feasible for the study nurse to deliver the intervention in the participant’s 
own GP practice as planned. The initial face-to-face appointments were typically around 60 
minutes long (SD=14.4). Two thirds of men did not require or wish a follow-up appointment 
(28/42). Nine men (21.4%) received one follow-up appointment, three men (7.1%) received 
two follow-up appointments and two men (4.7%) received three follow-up appointments. 
15/21(71.4%) follow-up appointments were conducted by telephone, which were, on 
average, 12 minutes long (SD=6.13). In addition all participants received a final follow-up 
telephone call. 
Views on the intervention 
Questionnaire findings 
Thirty men responded to the section of the questionnaire evaluating the nurse intervention. 
All found the intervention schedule to be appropriate to their needs, and of about the right 
duration. Most (n=26/29, 90%) found the initial face-to-face appointment and the telephone 
follow-up calls (n=23/29, 79%) to be useful/very useful. Over half (n=18/30, 60%) thought all 
men should definitely be routinely offered this sort of nurse-led care in primary care, and a 
further 33% (n=10/30) thought they probably should. Opinions were divided regarding the 
optimal time for this sort of support, with 30% (n=9/30) favouring at diagnosis, 40% 
(n=12/30) during initial treatment, and 30% (n=9/30) after initial treatment has finished. 
Interview findings 
Thirteen of those in the intervention group were interviewed (65% response rate), in 
addition to all five study nurses. Three main themes emerged from the analysis: 
Impact of the intervention: promoting active self-management and an improved 
sense of wellbeing  
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Men generally felt the intervention had been beneficial to their sense of wellbeing, and 
reported feeling reassured and more emotionally supported. They valued being able to talk 
about their emotions and fears in what they considered to be a safe and welcoming 
environment.  
‘I could speak openly to her - more so than my doctor, she understood everything I 
was worried about’  (ID:  493)   
‘…..because otherwise it’s just presented as a physical thing you’ve got and there’s 
that awful feeling…..you’ve got when you have cancer and it’s really good to have 
someone who says; well you can do this or that, you may feel this or you may feel 
that. So it’s just absolutely brilliant. It takes all the fear away’ (ID:10) 
Some men described greater feelings of control over their body and increased confidence in 
their ability to manage their condition and adopt more active coping strategies. Some noted 
improvements in their urinary, sexual or bowel functioning. 
‘getting more control over your body…which again is good, not to feel that you’ve 
been landed with something that just controls you rather than vice versa…[Nurse] 
helped me get my self-confidence back and indirectly improve sexual relations with 
my wife - and left us happy.’  (ID: 503)  ‘she gave me quite a number of handouts, 
which had information, when you take the exercises [pelvic floor], what you should 
do, all the things which the GPs hadn’t done...but this [study nurse] did seem very 
knowledgeable…and she did fill me with a certain degree of confidence’ (ID: 401)   
Men valued the opportunity to talk about issues such as sexual functioning, where previously 
embarrassment had been a barrier to seeking help. 
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‘I can sit and talk to [study nurse] about these sexual matters, and don’t feel 
embarrassed, I don’t know why, but… I don’t feel happy about going up to the 
hospital and seeing someone in the clinic’ (ID: 455) 
A few men reported no particular changes following the intervention in terms of their 
symptoms. These men either perceived few problems to begin with, or were reluctant to 
implement pelvic floor exercises or to see the GP regarding medications for sexual 
dysfunction.  
The intervention appeared to be particularly valued by men who perceived that their contact 
with health professionals was limited, or that there was a lack of holistic support after 
treatment completion and/or a lack of verbal or written information provided on dealing 
with symptoms.  
‘It was particularly good to be able to discuss one's personal problems frankly and at 
length with someone with plenty of relevant experience but not involved with one's 
treatment. Distance lends objectivity and time for reflection: not many GPs or hospital 
consultants can afford to give patients so much attention’  (ID: 459) 
Both men and nurses felt that this type of intervention was useful for men who had passively 
accepted their symptoms and for those who displayed gendered coping styles, such as 
avoiding help-seeking or talking to health professionals about their problems, prior to the 
intervention.  
‘the impotence that follows on, I had just accepted as being par for the course, and 
really a small price to pay, but she said well no, you shouldn’t have to just shrug and 
get on with it, if you want to do something about it here’s what you can do, and lots 
of advice on that, …that was all very encouraging and not making light of something 
that could be considered to be peripheral’ (ID: 503) 
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2: Nurses’ experiences of delivering the intervention  
In general, nurses felt the intervention worked very well, and found the training, resources 
and manual very helpful. Nurses mentioned the usefulness of asking men to complete a urine 
diary and urine chart prior in enabling them to assess urinary continence and advise men on 
bladder retraining.  
 ‘So the fluid balance and the urine, for me I felt was the thing I made the biggest 
impact on, really, of doing the bladder retraining’ (ID:2) 
As issues with forgetfulness and/or lack of motivation were reported in some men, the 
nurses felt the tailored follow-up design was particularly useful for addressing this. 
Nurses observed that many men lacked preparedness for life after prostate cancer 
treatment, so felt that these men particularly valued being given information during the 
intervention.  
‘I would say three or four of the six that I saw hadn’t had any [written] literature 
given to them at all…they found that particularly useful’ (ID 3) 
Nurses also felt that men had previously been reluctant to address their issues, sometimes 
due to lack of knowledge or embarrassment, so they felt able to motivate them to become 
more active.  
‘A lot of them were of the opinion, well, you know, I’m 70, can I really go to the GP 
and discuss it [sexual dysfunction]’ (ID: 1) 
Regarding the timing of the intervention, the study nurses felt that men who were several 
years post treatment already knew some of the advice they had to offer and/or had often 
learned to live with their symptoms and were less receptive to implementing behavioural 
changes, such as pelvic floor exercises., and that intervening earlier may be more beneficial. 
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‘some of the advice they already knew… so earlier might be better…’  (ID:5)A lot of 
them by two years [post-treatment] are slightly, well, I’ve been living like this for two 
years, I’m fine, I don’t really want to rock the boat, I don’t really want to change what 
I’m doing, so….’ (ID:1) 
Challenges in delivering the intervention 
Nurses reported some frustration at times over dealing with sexual dysfunction, in that while 
they felt they could be helpful at advising men on medication for sexual dysfunction and 
recommending men speak further to their GP, they were disappointed to find some men 
failing to act on this advice. While they acknowledged this area was not a priority for all men, 
and that some had accepted celibacy in their relationships or were no longer sexually active, 
they felt others could have benefited.  
Nurses also reported they that they found it quite challenging dealing with men who had 
already been told their sexual functioning may not return. 
‘… sometimes the professionals at the clinic had pretty much said to the man that 
there was nothing more really they can do, they had tried lots of different options 
already…. also specific questions that the men had asked me whether their sexual 
function would return, I found that quite hard to answer’ (ID: 3) 
Despite initial willingness from men, nurses also felt that their attempts to motivate men to 
exercise in order to improve fatigue were largely unsuccessful, and some attributed this to 
older age.   
In terms of future improvements to the training programme, nurses felt further training on 
how to deal with psychological issues, particularly fear of recurrence could be helpful.  
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‘I found it quite hard to deal with anxiety, depression, and the psychological side of 
things’ (ID: 3) 
Looking to the future, nurses felt that a trained practice (or other) nurse could deliver the 
intervention in primary care. However, because of the low numbers of men with prostate 
cancer in any one practice, to be effective and cost-effective they felt that one potential 
model would be for a nurse who is trained in cancer follow-up to work across practices. A 
couple of the study nurses experienced fairly long gaps between appointments which led to 
them feeling ‘de-skilled’.  
 
Patient reported outcomes 
Prostate-related quality of life  
No between-group differences were observed in the domain scores for urinary, bowel, sexual 
or hormone-related symptoms, although general deterioration from baseline over time was 
evident (apart from sexual function which improved). The proportion reporting moderate/big 
problems within each domain of the EPIC-26 can be found in Supplementary Material, 
Appendix A. Mean scores for each domain by study group, and the change from baselines are 
presented in Appendix B. 
Unmet needs, psychological well-being and self-efficacy 
There was a reduction in the proportion of patients reporting unmet need in both the 
intervention and control groups from baseline to post-intervention. The reduction was 
greater in the intervention group for four of the five domains of the SCNS-24, although this 
did not reach statistical significance (see Table 2). 
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No between-group differences in psychological well-being as measured by the HADS were 
observed (see Table 2). 
The intervention group reported improved self-efficacy across the majority of items. The 
most notable improvements related to being: ‘confident in keeping symptoms or other 
health problems from interfering with things you want to do’; ‘confident in contacting your 
doctor about any problems caused by cancer and/or cancer treatment’; and ‘confident that 
you can get support with problems caused by your cancer and/or cancer treatment from 
health and/or social care professionals’. However, these differences did not reach statistical 
significance (see Table 2). 
Resource Use 
Self-reported contacts with healthcare providers varied across contact type and by trial arm. 
Table 3 highlights the types of discussion that took place at healthcare visits and the extent 
to which this varied across trial arms.  A higher proportion of men reported discussing PSA 
test results (35/62) and implications of tumour growth/spread (14/17) in an outpatient 
setting with the consultant and/or clinic nurse in the control group compared to the 
intervention group; this was statistically significant for those discussing tumour growth or 
spread concerns (P = 0.021). A higher proportion of men in the intervention group discussed 
sexual (12/15) and urinary problems (12/14) with their GP in a primary care setting compared 
to the control group while higher proportions in the control group discussed these problems 
in an outpatient setting, neither,however, was statistically significant. A statistically 
significant difference was evident for the proportions of men who discussed bowel problems 
(25/36) across all settings in the intervention group (P < 0.01) relative to the control group; 
this discussion was predominantly in the primary care setting (see Table 3). 
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Discussion  
To our knowledge this is the first study to trial a primary-care based supportive care 
intervention for prostate cancer survivors in the UK. We have shown that our relatively brief 
intervention can be successfully delivered by nurses in primary care, and that it is acceptable 
to, and valued by, men. Whilst the qualitative evaluation clearly suggested that men gained a 
range of positive outcomes from the intervention, the benefits were less clear from analysis 
of the patient reported outcome measures used in the study, and although not powered to 
detect differences, it is possible that the intervention was not effective. 
Although men reported reduced levels of unmet needs and improved self-efficacy, we did 
not observe any between-group differences in prostate-related quality of life or psychological 
well-being. As already highlighted, this pilot study was not powered to detect statistically 
significant differences and therefore it is unclear whether the observed differences would be 
significant if a larger study was conducted. It is, however, encouraging that the intervention 
appeared to improve men’s confidence in their ability to keep any symptoms or other health 
problems from interfering with the things they wanted to do, and also appeared to improve 
men’s confidence in contacting their doctor about any cancer-related problems.Resource use 
varied between the trial groups, as did the type of resources utilised. Patients receiving the 
intervention reported a higher number of primary care visits while the control group 
reported a higher number of secondary care visits. We also found indications of a possible 
redistribution of resource use with men in the intervention group more likely to consult their 
GP regarding side-effects of treatment, whereas men in the control group were more likely 
to discuss PSA results and the implications of tumour growth with their hospital consultant. 
Given that secondary care services have a higher cost implication than services delivered in 
the community, the economic impact of the redistribution of care to a primary setting may 
be substantial. Cost-effectiveness has been reported elsewhere (Burns et al., 2017), and 
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concluded that the intervention could potentially be cost-effective based on the evidence 
assessed at the pilot stage. An Australian trial which evaluated a shared care model of post-
treatment follow-up found that the shared care model cost less to deliver and outcomes 
were similar (Emery et al., 2017). 
A number of issues warrant consideration when interpreting the study findings. Men were, 
on average, two years post-diagnosis when they entered the trial and intervening earlier may 
have been more effective (Giesler et al., 2005, Dieperink et al., 2013), as suggested by both 
the patients and nurses. Secondly, men were included in the study regardless of their disease 
status or treatment received. Whilst in some ways this was a strength of the study as it 
reflected routine primary care practice, it also meant the sample was very heterogeneous 
with only small numbers per treatment type, thus limiting the analysis and conclusions that 
could be drawn. Thirdly, levels of functioning, self-efficacy, and well-being were relatively 
high and rates of unmet need relatively low at baseline, making it harder to show any effect 
of the intervention – this has implications for further targeting of similar interventions in 
future. Finding ways to stratify those with the greatest needs or risks remains an important 
challenge for the provision of good quality cancer care (Watson et al., 2012). It is also 
possible that the quantitative outcome measures we used were not well-suited for the 
evaluation of our intervention. We were keen to implement more generic, well-validated 
questionnaires in our study to ensure robustness, however this may have meant that the 
benefits of our intervention were not fully captured.  
. We observed a level of disparity between the accounts of men who were interviewed, who 
were largely positive about the intervention, and the relatively small effects of the 
intervention on the quantitative patient reported outcome measures used. The HADS, for 
example, is designed to screen for potential clinical levels of anxiety and depression, and a 
measure of prostate-specific anxiety may have been more sensitive.  We did not find any 
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evidence of improvement in the proportions of men reporting moderate or big problems for 
any of the EPIC domains. This may be due to the timing of our intervention, where earlier 
intervention would have been required to improve functioning. Measures of self-efficacy, 
coping and unmet need are more likely to be useful outcome measures at the time we 
intervened in this study. Our follow-up period was also short (three months following the end 
of the intervention) and it is possible that longer follow-up may have yielded further benefits.  
Finally, participants in our study were almost exclusively white and further work is needed to 
establish the acceptability and usefulness of this and similar interventions in men from other 
ethnic groups, particularly men of African or Caribbean origin who have a higher incidence of 
prostate cancer. 
Several previous studies have trialled psychosocial interventions for men with prostate 
cancer in other settings and are the subject of a recent review (Chambers, 2017). Our study 
differs from previous studies in that it has tested a primary-care based intervention for 
prostate cancer survivors. In the UK the National Cancer Survivorship Initiative (NCSI) 
recommends a move away from traditional models of consultant-led hospital follow-up to a 
model of supported self-management in the community for stable, low risk patients 
(Department of Health et al., 2013). Previous studies have elicited patient concerns about 
GP-led follow-up (Lewis et al., 2009). However, men in our study were amenable to 
survivorship care being provided in primary care, provided it was delivered by someone who 
was knowledgeable. Similarly, the PROCARE study found men were equally satisfied with 
shared versus hospital-led follow-up care (Emery et al., 2017). 
We have shown that it is feasible to train nurses in primary care to deliver a relatively low –
intensity, low-cost intervention which supports and promotes self-management, is valued by 
men, and is potentially cost-effective. Costs could be reduced further by offering group 
sessions or using online support, although without some face-to-face contact we think it is 
22 
 
likely that at least some of the potential benefit of our intervention would be lost. Given the 
relatively low number of prostate cancer patients per individual UK general practice, a model 
whereby one nurse with expertise in this area works across a group or federation of practices 
may make sense, or a nurse within a given practice develops expertise in survivorship issues 
across the range of cancers commonly seen in primary care.  
In summary, this pilot trial adds to the evidence base regarding the provision of prostate 
cancer survivorship care. The findings indicate the potential value of a nurse-led intervention 
in primary care to promote self-management and reduce unmet needs. We believe a larger 
trial is warranted delivering the intervention earlier in the patient pathway.  
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Table 1: Patient characteristics by trial group allocation 
Participants Characteristics  Intervention 
Group 
(N=42)  
 
Mean (SD) 
Control Group  
(N=41)  
 
Mean (SD) 
Total  
(n=83)  
 
Mean (SD) 
Patient age (years)* 68.43 (7.43) 
Range 52-84 
68.68 (7.23) 
Range 51-83 
68.56 (7.29) 
Range 51-84  
Time since diagnosis* (months) 23.24 (5.31) 
Range 13-34 
24.01 (5.05 
Range 13-34 
23.62 (5.16) 
Range 13-34  
Age Group (years)*  N (%) N (%) N (%) 
50-59  6 (14.3) 6 (14.6) 12 (14.5) 
60-69 20 (47.6) 19 (46.3) 39 (47.0) 
70-79 14 (33.3) 12 (29.3) 26 (31.3) 
80-89 2 (4.8) 4 (9.8) 6 (7.2) 
Highest Educational Qualification     
GCSE’s or equivalent 7 (16.7) 7 (17.1) 14 (16.9) 
A-levels or equivalent 3 (7.1) 0 (0) 3 (3.6) 
Clerical or commercial  2 (4.8) 8 (19.5) 10 (12.0) 
College or University degree  10 (23.8) 11 (26.8) 21 (25.3) 
Postgraduate qualification  7 (16.7) 5 (12.2) 12 (14.5) 
None of these  13 (31.0) 10 (24.4) 23 (27.7) 
Employment    
Employed in paid work 17 (40.5) 15 (36.6) 32 (38.6) 
Temporarily off sick 0 (0) 1 (2.4) 1 (1.2) 
Retired 25 (59.5) 25 (61.0) 50 (60.2) 
Unemployed 0 (0) 0 (0) 0 (0) 
Long-term disability or ill health 0 (0) 0 (0) 0 (0) 
Full time education or training 0 (0) 0 (0) 0 (0) 
Marital status    
Married/cohabiting 36 (85.7) 37 (90.2) 73 (88.0) 
In partnership/not cohabiting 3 (7.1) 0 (0) 3 (3.6) 
Widowed 2 (4.8) 1 (2.4) 3 (3.6) 
Divorced/separated 1 (2.4) 2 (4.9) 3 (3.6) 
Single 0 (0) 0 (0) 0 (0) 
Other 0 (0) 1 (2.4) 1 (1.2) 
Ethnicity     
White British  41 (97.6) 39 (95.1) 80 (96.4) 
White – Other 1 (2.4) 1 (2.4) 2 (2.4) 
Black- Other  0 (0) 0 (0) 0 (0) 
Chinese  0 (0) 0 (0) 0 (0) 
Other  0 (0) 1 (2.4) 1 (1.2) 
Previous Treatment (Primary) **    
Surgery  15 (35.7) 10 (24.3) 25 (30.1) 
Radiotherapy – external beam 4 (9.5) 5 (12.1) 9 (10.8) 
Radiotherapy- plus hormone 12 (28.6) 10 (24.3) 22 (26.5) 
Hormone only 3 (7.1) 3 (7.3) 6 (7.2) 
Active surveillance  3 (7.1) 6 (14.6) 9 (10.8) 
Other  1 (2.4) 0 (0) 1 (1.2) 
Co-morbidities    
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   Heart problems 7 (16.7) 7 (17.1) 14 (16.9) 
   High blood pressure 11 (26.2) 14 (34.1) 25 (30.1) 
   COPD*** 2 (4.8) 1 (2.4) 3 (3.6) 
   Asthma 3 (7.1) 3 (7.3) 6 (7.2) 
   Diabetes 6 (14.3) 5 (12.2) 11 (13.3) 
   Arthritis 6 (14.3) 8 (19.5) 14 (16.9) 
   Osteoporosis 2 (4.8) 0 (0) 2 (2.4) 
   Inflammatory bowel disease 0 (0) 1 (2.4) 1 (1.2) 
   Multiple Sclerosis 0 (0) 0 (0) 0 (0) 
   Parkinson’s disease 0 (0) 0 (0) 0 (0) 
   Other 10 (23.8) 5 (12.2) 15 (18.1) 
   At least one co-morbidity 25 (59.5) 25 (61.0) 50 (60.2) 
   No co-morbidities 17 (40.5) 16 (39.0) 33 (39.8) 
*At point of randomisation into the study;  ** Some men had received more than one type of treatment 
***Chronic Obstructive Pulmonary Disease 
  
28 
 
Table 2: Mean outcomes at baseline and follow up and differences between 
intervention and control groups 
Self-efficacy scores (possible range 1-10) 
 
Intervention (N=38) Control (N=34) 
Baseline 7mth f/u Difference (95% CI) Baseline 7mth f/u 
Difference 
(95% CI) 
Fatigue 7.84 8.11 0.26 (-0.39, 0.92) 8.18 8.29 
0.12 
(-0.44, 0.67) 
Discomfort 8.45 8.76 0.32 (-0.50, 1.14) 8.82 8.41 
-0.41 
(-0.96, 0.14) 
Emotional 
Distress 8.32 8.47 
0.16 
(-0.73,1.04) 8.21 8.18 
-0.03 
(-0.53, 0.47) 
Symptoms 7.55 8.58 1.03 (0.21, 1.85) 7.97 7.79 
-0.18 
(-0.90, 0.54) 
Manage Tasks 8.74 8.71 -0.03 (-0.73, 0.68) 9.00 8.41 
-0.59 
(-1.21, 0.04) 
Do Other Things 8.47 8.45 -0.03 (-0.80, 0.74) 7.88 7.79 
-0.09 
(-1.13, 0.95) 
Access 
Information 8.53 8.58 
0.05 
(-0.54, 0.65) 8.50 7.79 
-0.71 
(-1.59, 0.18) 
Access People 8.26 8.24 -0.03 (-0.69, 0.63) 8.21 7.76 
-0.44 
(-1.15, 0.26) 
Deal By Yourself 7.97 6.87 -1.11 (-2.08, -0.13) 7.71 7.32 
-0.38 
(-1.31, 0.54) 
Contact Doctor 8.63 8.82 0.18 (-0.61, 0.98) 8.68 7.94 
-0.74 
(-1.37,-0.10) 
Get Support 7.76 8.18 0.42 (-0.27, 1.11) 8.12 7.15 
-0.94 
(-1.78, -0.10) 
Unmet needs domain scores (possible range)  
Psychological 
(10-50) 18.32 15.70 
-2.62  
(-4.51, -0.74) 17.18 16.00 
-1.18 
(-3.70, 1.34) 
Health System 
& Information 
(11-55) 
19.66 17.39 
-2.26  
(-4.46, -0.06) 19.88 17.94 
-1.94 
(-4.99, 1.11) 
Physical & Daily 
Living 
(5-25) 
7.70 7.00 
-0.70  
(-1.67, 0.26) 6.91 6.82 
-0.15  
(-0.92, 0.62) 
Patient Care & 
Support 
(5-25) 
7.39 6.79 
-0.61  
(-1.48, 0.27) 7.56 6.88 
-0.68 
(-1.77, 0.42) 
Sexuality 
(3-15) 7.03 5.19 
-1.84  
(-3.03, -0.64) 6.56 5.32 
-1.26 
(-2.24, -0.29) 
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Hospital Anxiety and Depression Scare (HADS) 
 
Intervention (N=38) Control (N=34) 
Baseline 7mth f/u Difference (95% CI) Baseline 7mth f/u 
Difference 
(95% CI) 
Mean 
Depression 
Score 
2.80 2.74 0.06 (-0.62, 0.74) 2.88 3.19 
-0.31  
(-1.00, 0.38) 
Mean  
Anxiety  
Score 
3.79 4.26 -0.47 (-1.33, 0.39) 4.19 3.94 
0.25  
(-0.52, 1.02) 
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Table 3: Self-reported healthcare visits by discussion type 
 
Visit Typea Discussed PSA rResult at visit type No Did not 
dDiscussion of 
PSA rResult 
Total Visits 
Reported 
 Total Intervention Control   
1- GP Visit 19 10 9 53 72 
2- Practice Nurse 9 2 7 97 106 
3- District Nurse 0 0 0 1 1 
4- Macmillan Nurse 0 0 0 1 1 
5- Physiotherapist 1 0 1 1 2 
6- Occupational 
therapist 
0 0 0 1 1 
9- Hospital Consultant 42 18 24 25 67 
10- Hospital Nurse 20 9 11 19 39 
11- Other* 4 3 1 22 26 
Not Classified 0 0 0 2 2 
Missing 1  1 1 2 
Visit Type Discussed tumour growth/ spread 
at visit type 
Did notNo 
dDiscussion of 
tumour 
growth/ 
spread 
Total Visits 
Reported 
 Total Intervention Control   
1- GP Visit 2 1 1 70 72 
2- Practice Nurse 0 0 0 106 106 
3- District Nurse 0 0 0 1 1 
4- Macmillan Nurse 0 0 0 1 1 
5- Physiotherapist 0 0 0 2 2 
6- Occupational 
therapist 
0 0 0 1 1 
9- Hospital Consultant 13 2 11 54 67 
10- Hospital Nurse 4 1 3 35 39 
11- Other* 1 1 0 25 26 
Not Classified 0 0 0 2 2 
Missing    2 2 
Visit Type Discussed  sexual problems at visit 
type 
No Did not 
dDiscussion of 
sexual 
problems 
Total Visits 
Reported 
 Total Intervention Control   
1- GP Visit 15 12 3 57 72 
2- Practice Nurse 3 0 3 103 106 
3- District Nurse 0 0 0 1 1 
4- Macmillan Nurse 0 0 0 1 1 
5- Physiotherapist 1 0 1 1 2 
6- Occupational 
therapist 
1 0 1 0 1 
9- Hospital Consultant 9 4 5 58 67 
10- Hospital Nurse 17 7 10 22 39 
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11- Other* 7 6 1 19 26 
Not Classified 0 0 0 2 2 
Missing    2 2 
Visit Type Discussed  urinary problems at visit 
type 
Did not No 
dDiscussion of 
urinary 
problems 
Total Visits 
Reported 
 Total Intervention Control   
1- GP Visit 14 12 2 58 72 
2- Practice Nurse 1 0 1 105 106 
3- District Nurse 0 0 0 1 1 
4- Macmillan Nurse 0 0 0 1 1 
5- Physiotherapist 1 0 1 1 2 
6- Occupational 
therapist 
1 0 1 0 1 
9- Hospital Consultant 12 5 7 55 67 
10- Hospital Nurse 14 6 8 25 39 
11- Other* 2 2 0 24 26 
Not Classified 0 0 0 2 2 
Missing   1 1 2 
Visit Type Discussed  bowel problems at visit 
type 
No Did not 
dDiscussion of 
bowel 
problems 
Total Visits 
Reported 
1- GP Visit 13 10 3 59 72 
2- Practice Nurse 1 0 1 105 106 
3- District Nurse 0 0 0 1 1 
4- Macmillan Nurse 0 0 0 1 1 
5- Physiotherapist 1 0 1 1 2 
6- Occupational 
therapist 
0 0 0 1 1 
9- Hospital Consultant 10 6 4 57 67 
10- Hospital Nurse 5 3 2 34 39 
11- Other* 6 6 0 20 26 
Not Classified 0 0 0 2 2 
Missing    2 2 
a. Participants reported type of healthcare visit in trial dairies and also highlighted the 
topic of discussion, based on the five sub-groups presented, at each visit.  
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Appendix  A. Proportion in each group reporting moderate or large overall problems at 
baseline and after the intervention. 
Overall 
Problems 
Intervention Control 
Mod/Big Problem (%) Mod/Big Problem (%) 
N Baseline 7mth f/u N Baseline 7mth f/u 
Urinary 
function 37 22% 16% 33 27% 18% 
Bowel 
habits 37 14% 19% 34 9% 6% 
Sexual 
function 35 46% 46% 33 55% 33% 
Hot Flushes 35 23% 14% 33 21% 18% 
Breast 
Tenderness 33 6% 3% 32 3% 13% 
Feeling 
Depressed 32 3% 9% 32 6% 10% 
Lack of 
Energy 35 23% 37% 34 24% 18% 
Change in 
Body 
Weight 
32 19% 9% 33 18% 12% 
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Appendix B:  Mean domain scores at baseline and post-intervention in each arm 
  
Intervention Control 
N Baseline 7mth f/u 
Difference 
(95% CI) N Baseline 
7mth 
f/u 
Difference 
(95% CI) 
Urinary 
Incontinence 32 81.88 79.27 
-2.61 
(-7.68, 2.46) 30 82.46 80.04 
-2.42 
(-6.47,1.64) 
Urinary 
Irritate/ 
Obstructive 
31 84.88 64.31 -20.56 (-25.77, -15.36) 26 84.13 62.26 
-21.88 
(-29.17, -14.58) 
Bowel 28 91.49 73.07 -18.42 (-22.77, -14.08) 31 88.84 68.20 
-20.65 
(-26.08, -15.22) 
Sexual 33 20.81 29.33 8.53 (0.93, 16.12) 31 25.80 30.96 
5.16 
(0.70, 9.62) 
Hormonal 33 79.85 59.70 -20.15 (-25.14, -15.17) 30 80.33 57.92 
-22.52 
(-27.47, -17.36) 
 
 
 
 
 
 
 
Allocation 
 
 
 
 
 
 
*Health Resource Use questionnaires 
Enrolment 
Invited to phase 1 = 546 
Total returned questionnaires = 369 
316/493 (64%) eligible Phase 1 
participants completed questionnaire , 
of which: 
242/316 (77%) reported ongoing 
problems 
177/242 (73%) were interested in 
phase 2 
 
 
Invited to phase 2 = 136/177 
Agreed to be in phase 2 = 83 (61%) 
Eligible, but 
declined to 
participate = 177 
 
Excluded as ineligible = 53 
Allocated to intervention group = 42 
Received intervention = 42 
Did not receive intervention = 0 
Allocated to control group (usual care) = 41 
Received usual care = 41 
Did not receive usual care = 0 
Follow-Up 
Discontinued intervention = 2 
One patient had recurrence/high PSA and no longer 
fitted inclusion criteria, one patient withdrew due to 
unrelated health problems 
Incomplete intervention = 1 
Patient had all designated appointments and 
completed questionnaire 2, but could not be 
reached for 6 month follow up call 
Analysis 
Lost to follow up= 2 
Not returned  final questionnaire 
Follow up qst returned =38/40 (95%) 
•   HRU1* = 38/40 
•   HRU2 = 35/40 
•   HRU3 = 34/40 
• Filled all 3 HRU = 32/40 
Analysed = 38 
Excluded from analysis (n= 2 patients 
who discontinued intervention) 
Lost to follow-up = 7 
No response to contact from research team 
• Follow up qst returned =34 (83%) 
•   HRU1 = 31 
•   HRU2 = 31 
•   HRU3= 30 
• Filled all 3 HRU = 27 
Analysed  (n=34, including partial data 
sets, where pt was LTFU) 
Excluded from analysis  (n= 0) 
Figure 1: Recruitment flow diagram 
